# Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

> **NCT07126288** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shenzhen Kexing Pharmaceutical Co., Ltd.** · enrollment: 268 (estimated)

## Conditions studied

- Growth Hormone Deficiency in Children
- Growth Hormone Deficiency (GHD)
- Growth Hormone

## Interventions

- **DRUG:** GB08
- **DRUG:** Norditropin NordiFlex

## Key facts

- **NCT ID:** NCT07126288
- **Lead sponsor:** Shenzhen Kexing Pharmaceutical Co., Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2028-09-15
- **Final completion:** 2028-12-23
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07126288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07126288, "Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07126288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*